Krystal Biotech (KRYS) said Monday its Vyjuvek treatment for dystrophic epidermolysis bullosa received marketing authorization from the European Commission.
The decision allows the marketing of the treatment in all EU member states, as well as Iceland, Norway and Liechtenstein, with availability subject to multiple factors, the company said.
Krystal said it is planning for the treatment's first European launch in Germany in mid-2025.
Shares were up 2% in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.